Inflammatory Bowel Disease

WASHINGTON — Although a greater number of patients with Crohn’s disease who failed anti-TNF therapy achieved biologic remission with Skyrizi vs. Stelara, choosing between the two therapies “still remains on the table,” a researcher noted.

WASHINGTON — Statin use was associated with up to a 90% risk reduction for new-onset primary sclerosing cholangitis among patients with inflammatory bowel disease, according to data presented at Digestive Disease Week.

In a Healio exclusive, Ari Grinspan, MD, predicted that while microbiota therapeutics are currently “not ready for prime time,” they will eventually become part of the treatment strategy for patients with inflammatory bowel disease.

Novel forms of a rare genetic variant may contribute to the risk for co-occurring Parkinson’s disease and inflammatory bowel disease, according to research presented in Genome Medicine.

Approximately two-thirds of patients with Crohn’s disease who initially responded to anti-tumor necrosis factor therapy lost response by 3 years, with researchers suggesting that higher drug concentrations at induction may improve outcomes.

Tumor necrosis factor inhibitor use was independently associated with a greater risk for progressive kidney function decline but not risk for all-cause mortality among patients with new-onset inflammatory bowel disease, according to data.

The FDA has issued a safety alert warning patients and health care providers of a “rare risk of intrahepatic cholestasis of pregnancy” linked to thiopurine use.

Pretreatment with budesonide did not significantly influence engraftment among patients with ulcerative colitis who underwent fecal microbiota transplantation, with researchers reporting that clinical response appeared to be donor-dependent.

BOSTON — Chronic diarrhea is an “incredibly common” condition, with about one out of 20 patients presenting with symptoms, according to Brian E. Lacy, MD, PhD, FACG, a professor of medicine at the Mayo Clinic.

Despite a class-wide black box warning for prescribing in the early setting, 31% of providers reported positioning Janus kinase inhibitors as first-line treatment among patients with severe ulcerative colitis, according to survey results.